Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
First post for me...it's been interesting reading these perspectives.
It's hard to swallow when people see someone buying lower than me for the same stock, but I think it's meant to encourage more buying than bragging. When I bought IMMU online, my quote was for $28, then the phone rang and I had to re-do it, then it was $32! Then I bought thinking it was $30 and it ended up being $32! Now today it was $25...
The point being is that the long haul is the key and this forum let's us vent and compare.
Shout out to drtstocks, what's your specialty?
Print the post Back To Top
No. of Recommendations: 5
My specialty is gastroenterology,
I am bullish on this company because the response that I have seen with infliximab in the treatment of Crohn's disease. This antibody to TNF alpha took patients who had terrible fistulas and were steroid depedent and gave them their lives and dignity back. Fully 80% of patients, with a series of three infusions, resolved fistulas that have been present for years. The majority also came off of their steroids which they had been dependent on for years. We were very skeptical at first about efficacy and potential side effects (such as serum sickness) with repeated dosing, but none of this has materialized.
Embrel is routinely given to patients with RA but it works equally well in patients with arthropathy due to inflammatory bowel disease (not FDA approved for this indication however).
Humanized antibody therapy will be enormous in the next 5-10 years and IMMU is well positioned to take full advantage of the revolution (especially with all their patents for antibody humanization). IMO given 2-3 years the genome sequencing stocks that are so hot right now will fall. Although the information is invaluable the application of that knowledge will be decades away. Investors will treat them like internet stocks and eventually get tired of seeing them loose money. IMMU is on the verge of launching some products that could be and will be huge based on initial data.
The announcement today simply shows the numerous applications of this technology. Picture it ...When someone is diagnosed with colon cancer (still the third leading cause of cancer deaths in the U.S.)and it produces CEA, (about 75-80%) we can send them for a PET scan with this radiolabeled antibody and tell exactly where any metastasis or micrometastasis may be including the lymph nodes. Information like this will be invaluable to a surgeon doing the resection. It will allow them to make sure all the areas that light up are thoroughly dissected. It may also save some people from surgery by demonstrating that the lesion is too far advanced. This technology is exciting and I plan to hold this stock for the above reasons. IMO those who hold this stock had better tape on their shoes because it is going to take off and not look back.
Print the post Back To Top
No. of Recommendations: 0
drtstocks--

Well said. I am a long term holder of this company as well and have the same opinion that this technology is in its infancy. It is speculation that the FDA support will occur, but a risk worth taking. What is the current competetion for IMMU? About 1/2 of my portfolio consists of biotech companies in their infancy. This has been rewarding recently--but only due to the recent interest in these stocks. Once again, thanks for the informative post.

tracer
Print the post Back To Top
No. of Recommendations: 0
Drtstocks--
Thanks for the insights...
Dermatologist here, and I heard about some similar applications for Embrel in psoriatic arthropathy/spondyloarthropathy but nothing recently.
Also wondering about helpful references e.g. Medical Letter to stay ahead for investing as well as new drug info.

Print the post Back To Top
No. of Recommendations: 0
Let me check my sources for additional companies in the antibody field with outstanding potential and I will get back to you guys.
Print the post Back To Top
No. of Recommendations: 0
Hey doc,

Great insight please keep us posted!!
Print the post Back To Top